CGRPlahendusi
CGRPlahendusi is a term used to describe a family of interventions that aim to modulate the calcitonin gene-related peptide (CGRP) pathway to prevent or treat migraine and related disorders. The word combines CGRP with lahendus, a word meaning "solution" in Estonian, and is used in some European scientific contexts to denote CGRP-based therapeutic strategies.
Categories within CGRPlahendusi include monoclonal antibodies that target CGRP or its receptor, small-molecule CGRP receptor antagonists
CGRP is a neuropeptide involved in vasodilation and nociceptive signaling in the trigeminovascular system. Inhibiting CGRP
Clinical development has led to several approved agents and ongoing research. Monoclonal antibodies against CGRP or
Safety monitoring continues for long-term use, with common adverse events including injection-site reactions for antibodies and